Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Using cost-effectiveness analysis for formulary decision making: from theory into practice.

A S Detsky1

  • 1Departments of Health Administration and Medicine, University of Toronto, Ontario, Canada.

Pharmacoeconomics
|September 5, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Do you come to work with a respiratory tract infection?

Occupational and environmental medicine·2009
Same author

What is subjective global assessment of nutritional status? 1987. Classical article.

Nutricion hospitalaria·2008
Same author

Effect of restricting contact between pharmaceutical company representatives and internal medicine residents on posttraining attitudes and behavior.

JAMA·2001
Same author

Screening for colon cancer--can we afford colonoscopy?

The New England journal of medicine·2001
Same author

The application of decision analysis to the surgical treatment of early osteoarthritis of the wrist.

The Journal of bone and joint surgery. British volume·2001
Same author

Recruiting researchers.

Clinical and investigative medicine. Medecine clinique et experimentale·2001
Same journal

Balancing Access and Value in Multi-Indication Medicines: Implications of PD-L1 Broad Listings in Australia.

PharmacoEconomics·2026
Same journal

Applications of Structural Expert Elicitations for Economic Evaluations: A Systematic Review Update.

PharmacoEconomics·2026
Same journal

Community Pharmacist Preferences for Providing a Dose Administration Aid Service in Australia: A Discrete Choice Experiment.

PharmacoEconomics·2026
Same journal

A Critical Systematic Review of Modelling Approaches and Methodologies used in Hyperlipidaemia Economic Evaluations.

PharmacoEconomics·2026
Same journal

Deriving a Korean SF-6Dv2 Value Set Using a Discrete Choice Experiment with Duration.

PharmacoEconomics·2026
Same journal

Correction: Ten Recommendations for Modelling Cost Effectiveness of Screening: Perspectives of an International Stakeholder Group.

PharmacoEconomics·2026
See all related articles

Cost-effectiveness analysis (CEA) helps healthcare payers assess the value of pharmaceutical products beyond price. Practical application of CEA requires changes for better decision-making.

Area of Science:

  • Health Economics
  • Pharmaceutical Policy

Background:

  • Rising healthcare and pharmaceutical expenditures pose challenges for third-party payers due to limited market discipline.
  • Cost-effectiveness analysis (CEA) offers a systematic approach for payers to evaluate the value for money of healthcare interventions and pharmaceutical products.

Purpose of the Study:

  • To explore the transition of cost-effectiveness analysis from academic theory to practical application in healthcare decision-making.
  • To identify necessary changes for the systematic adoption of CEA by formulary committees.

Main Methods:

  • The study reviews the principles of cost-effectiveness analysis, emphasizing its comprehensive approach to costs and benefits over simple unit price comparisons.
  • It discusses the practical implementation challenges and required adaptations for integrating CEA into formulary decision-making processes.

Related Experiment Videos

Main Results:

  • The adoption of CEA by formulary committees necessitates defining its purpose, standardizing outcome measurement and data collection, and refining report formats.
  • Contractual agreements between the pharmaceutical industry and analysts are crucial for practical CEA implementation.

Conclusions:

  • The practical application of cost-effectiveness analysis in healthcare decision-making is evolving.
  • Increased real-world experience with CEA will enhance data quality and its utility in guiding payer decisions, ultimately improving value for money in pharmaceutical procurement.